This information is intended for use by health professionals
Prochlorperazine maleate 3 mg Buccal Tablets
Each buccal tablet contains 3.0 mg prochlorperazine maleate
Excipient with known effect: Compressible sugar (contains sucrose) 52.490 mg
For the full list of excipients, see section 6.1.
Yellow colored, circular shaped biconvex uncoated tablet debossed with 'C77' on one side and plain on other side with approximately 5.5 mm in diameter.
Symptomatic treatment of vertigo due to Ménière's Disease, Labyrinthitis and other causes. For nausea and vomiting from whatever cause. In the treatment of migraine.
To be placed in the buccal cavity, high up along the top gum under the upper lip, until dissolved. Do not chew or swallow the tablet.
Adults and children aged 12 years and over: One or two tablets twice a day.
Children under 12 years: Not recommended.
Elderly patients: There is no evidence that dosage need be modified for the elderly.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• Impaired liver function
• Existing blood dyscrasias
• Parkinsons Disease
• Prostatic hypertrophy
• Narrow angle glaucoma
Prochlorperazine 3 mg Buccal Tablets should be avoided in patients with stroke risk factors and myasthenia gravis.
Agranulocytosis has been reported with phenothiazines. The occurrence of unexplained infections or fever may be evidence of blood dyscrasia (see section 4.8), and requires immediate haematological investigation.
It has been reported that patients with AIDS may be particularly susceptible to antipsychotic-induced extrapyramidal effects.
Because of the risk of photosensitisation, patients should be advised to avoid exposure to direct sunlight and use sunscreen (see section 4.8).
Hypotension, usually postural, may occur, particularly in elderly or volume depleted patients.
Nausea and vomiting as a sign of organic disease may be masked by the anti-emetic action.
Neuroleptic malignant syndrome (NMS) is a potentially fatal symptom complex associated with antipsychotic medicinal products. Alteration in mental status and other neurological signs often precede systemic signs of NMS. It is imperative that treatment be discontinued in the event of NMS (characterised by unexplained fever, hyperthermia, autonomic dysfunction, altered consciousness, muscle rigidity) (see section 4.8).
Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment, and preventive measures undertaken (see section 4.8).
Increased Mortality in Elderly people with Dementia
Data from two large observational studies showed that elderly people with dementia who are treated with antipsychotics are at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known.
Prochlorperazine 3mg Buccal Tablets is not licensed for the treatment of dementia-related behavioural disturbances.
The tablet contain sucrose
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not use this medicine.
Alcohol and CNS depressants should be used with caution due to the possible additive CNS depressant effect.
The hypotensive effect of antihypertensive drugs may be exaggerated.
The mild anticholinergic effect of neuroleptics may be enhanced by other anticholinergic drugs.
Oral anticoagulants – may have diminished effect.
Anticonvulsants – efficacy may be diminished necessitating dosage adjustment, as prochlorperazine may lower the seizure threshold.
The concomitant use of lithium may result in severe extrapyramidal side effects or severe neurotoxicity.
The concurrent use of desferrioxamine and prochlorperazine should be avoided.
Prochlorperazine opposes the effects of levodopa.
There is inadequate evidence of the safety in human pregnancy. There is evidence of harmful effects in animals. Prochlorperazine Maleate 3 mg Buccal Tablets should be avoided pregnancy unless the physician considers it essential. Neuroleptics may occasionally prolong labour and at such time should be withheld until the cervix is dilated 3-4 cm. Possible adverse effects on the neonate include lethargy or paradoxical hyperexcitability, tremor and low apgar score.
Neonates exposed to antipsychotics (including prochlorperazine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.
Since data from animal studies shows that prochlorperazine may be found in breast milk, Prochlorperazine Maleate 3 mg Buccal Tablets should not be used during breastfeeding.
There are no data from on the effects of prochlorperazine on fertility.
Patients who drive or operate machinery should be warned of the possibility of drowsiness.
Undesirable effects are listed by MedDRA System Organ Classes. Assessment of undesirable effects is based on the following frequency groupings:
Very common: ≥1/10
Common: ≥1/100 to <1/10
Uncommon: ≥1/1,000 to <1/100
Rare: ≥1/10,000 to <1/1,000
Very rare: <1/10,000
Not known: cannot be estimated from the available data
Tabulated list of adverse reactions
System organ class
Undesirable effect and frequency
Blood and lymphatic system disorders
Immune system disorders
Hypersensitivity reactions such as rash and angioedema
Hyperprolactinaemia which may result in gynaecomastia, galactorrhoea and amenorrhoea
Metabolism and nutrition disorders
Syndrome of inappropriate antidiuretic hormone secretion
Glucose tolerance impaired
Nervous system disorders
Extrapyramidal reactions including acute dystonia, akathisia, parkinsonism and tardive dyskinesia
Hypotension (usually orthostatic)
Skin and subcutaneous tissue disorders
Photosensitivity (see section 4.4)
Pregnancy, puerperium and perinatal conditions
Drug withdrawal syndrome neonatal (see Section 4.6)
Description of selected adverse reactions
Impotence, ejaculation disorder, priapism, and agranulocytosis (see section 4.4) are class effects associated with phenothiazines.
Neuroleptic malignant syndrome may occur with any neuroleptic (see section 4.4).
Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic drugs- Frequency unknown (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The signs and symptoms will be predominantly extrapyramidal and may be accompanied either by restlessness and agitation or central nervous depression. Hypotension may also occur. Treatment is essentially symptomatic and supportive. There is no specific antidote. Do not induce vomiting. Particular attention must be directed to maintaining a clear airway since this may be threatened by extrapyramidal muscle dystonias. Severe dystonic reactions usually respond to procyclidine or orphenadrine given i.m. or i.v. If convulsions occur they should be treated using i.v. diazepam. If hypotension is present, strict attention to ventilation and posturing of the patient will often secure the desired effect, but failing this, consideration should be given to volume expansion by i.v. fluids. If this is insufficient, positive inotropic agents such as dopamine may be tried, but peripheral vasoconstrictor agents are not generally recommended. Adrenaline should NOT be used.
Pharmacotherapeutic group: Phenothiazines with piperazine structure
ATC code: N05AB04
Prochlorperazine is a member of the phenothiazine group of neuroleptics which, in doses lower than those used in psychiatry, is usually employed for its anti-emetic properties. The site of action is thought to be the chemoreceptor trigger zone.
The buccal tablets are placed in the buccal cavity where they form a gel from which the prochlorperazine is released and absorbed. The plasma levels achieved at steady-state on a dosage regimen of one buccal tablet twice daily are similar to those observed with the standard oral dosage of one 5 mg tablet taken three times daily. The elimination half-life of prochlorperazine in this formulation is 9.0 hours, similar to that observed with the oral formulation.
There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SmPC.
Locust bean gum
Riboflavin 5-phosphate sodium
This medicinal product does not require any special storage conditions.
PVC/PVdC aluminium foil blisters.
Blister packs of 2, 8, 15, 30, 50, or 60 buccal tablets
Not all pack sizes may be marketed
Any unused medicinal product or waste material should be disposed of in accordance with local requirements
Brown & Burk UK Ltd
5 Marryat Close